CL2020002247A1 - Compuestos macrociclicos derivados de peptidilo sustituidos (divisional de solicitud n° 01001-2016) - Google Patents
Compuestos macrociclicos derivados de peptidilo sustituidos (divisional de solicitud n° 01001-2016)Info
- Publication number
- CL2020002247A1 CL2020002247A1 CL2020002247A CL2020002247A CL2020002247A1 CL 2020002247 A1 CL2020002247 A1 CL 2020002247A1 CL 2020002247 A CL2020002247 A CL 2020002247A CL 2020002247 A CL2020002247 A CL 2020002247A CL 2020002247 A1 CL2020002247 A1 CL 2020002247A1
- Authority
- CL
- Chile
- Prior art keywords
- divisional application
- macrocyclic compounds
- derived macrocyclic
- substituted peptidyl
- peptidyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/126—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
En la presente invención se describen compuestos macrocíclicos derivados de peptidilo sustituidos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361896308P | 2013-10-28 | 2013-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020002247A1 true CL2020002247A1 (es) | 2021-02-05 |
Family
ID=53004986
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016001001A CL2016001001A1 (es) | 2013-10-28 | 2016-04-27 | Profármacos y moduladores de receptores nmda, sales y usos de estos |
CL2020002247A CL2020002247A1 (es) | 2013-10-28 | 2020-08-31 | Compuestos macrociclicos derivados de peptidilo sustituidos (divisional de solicitud n° 01001-2016) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016001001A CL2016001001A1 (es) | 2013-10-28 | 2016-04-27 | Profármacos y moduladores de receptores nmda, sales y usos de estos |
Country Status (15)
Country | Link |
---|---|
US (2) | US9745342B2 (es) |
EP (2) | EP3062810A4 (es) |
JP (1) | JP6603668B2 (es) |
KR (1) | KR20160077153A (es) |
CN (2) | CN105764522A (es) |
AU (2) | AU2014342624A1 (es) |
BR (1) | BR112016009443A8 (es) |
CA (1) | CA2928701A1 (es) |
CL (2) | CL2016001001A1 (es) |
IL (1) | IL245302B (es) |
MX (2) | MX2016005510A (es) |
RU (1) | RU2016119830A (es) |
SA (1) | SA516371037B1 (es) |
SG (2) | SG11201603376UA (es) |
WO (1) | WO2015065891A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2948140T3 (en) | 2013-01-22 | 2017-08-21 | Vistagen Therapeutics Inc | DOSAGE FORMS AND THERAPEUTIC APPLICATIONS OF L-4-CHLORCYNURENINE |
CN116082461B (zh) * | 2022-10-14 | 2023-11-14 | 浙江大学 | 一种具有抗菌活性的小分子肽及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1801118A4 (en) | 2004-09-14 | 2009-09-02 | Shionogi & Co | METHOD FOR SYNTHESIS OF MUCIN-TYPE PEPTIDES AND GLUCKOPEPTIDES RELATED TO MUC1 |
CA2686827C (en) * | 2006-12-14 | 2014-09-16 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
AU2008218116B2 (en) * | 2007-02-23 | 2012-04-05 | Aileron Therapeutics, Inc. | Triazole macrocycle systems |
WO2010033757A1 (en) * | 2008-09-18 | 2010-03-25 | Naurex, Inc. | Nmda receptor modulators and uses thereof |
CA2737921C (en) * | 2008-09-22 | 2019-01-15 | Aileron Therapeutics, Inc. | Methods for preparing purified alpha-helical peptidomimetic macrocycle compositions with low metal ppm levels |
KR101692275B1 (ko) * | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | 2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도 |
SG10201501050RA (en) * | 2010-02-11 | 2015-04-29 | Univ Northwestern | Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof |
MX357761B (es) * | 2011-04-27 | 2018-07-23 | Univ Northwestern | Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos. |
-
2014
- 2014-10-27 KR KR1020167013971A patent/KR20160077153A/ko not_active Application Discontinuation
- 2014-10-27 US US15/033,031 patent/US9745342B2/en active Active
- 2014-10-27 SG SG11201603376UA patent/SG11201603376UA/en unknown
- 2014-10-27 WO PCT/US2014/062367 patent/WO2015065891A1/en active Application Filing
- 2014-10-27 EP EP14858298.4A patent/EP3062810A4/en not_active Withdrawn
- 2014-10-27 AU AU2014342624A patent/AU2014342624A1/en not_active Abandoned
- 2014-10-27 MX MX2016005510A patent/MX2016005510A/es unknown
- 2014-10-27 EP EP19159957.0A patent/EP3564256A1/en not_active Withdrawn
- 2014-10-27 JP JP2016552196A patent/JP6603668B2/ja not_active Expired - Fee Related
- 2014-10-27 CN CN201480064349.XA patent/CN105764522A/zh active Pending
- 2014-10-27 CN CN202010688442.5A patent/CN112321678A/zh active Pending
- 2014-10-27 SG SG10201810496XA patent/SG10201810496XA/en unknown
- 2014-10-27 RU RU2016119830A patent/RU2016119830A/ru unknown
- 2014-10-27 BR BR112016009443A patent/BR112016009443A8/pt not_active IP Right Cessation
- 2014-10-27 CA CA2928701A patent/CA2928701A1/en not_active Abandoned
-
2016
- 2016-04-25 IL IL245302A patent/IL245302B/en active IP Right Grant
- 2016-04-27 MX MX2021000029A patent/MX2021000029A/es unknown
- 2016-04-27 CL CL2016001001A patent/CL2016001001A1/es unknown
- 2016-04-28 SA SA516371037A patent/SA516371037B1/ar unknown
-
2017
- 2017-07-24 US US15/658,107 patent/US10590167B2/en not_active Expired - Fee Related
-
2020
- 2020-02-17 AU AU2020201109A patent/AU2020201109A1/en not_active Abandoned
- 2020-08-31 CL CL2020002247A patent/CL2020002247A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL245302B (en) | 2020-05-31 |
JP2016537413A (ja) | 2016-12-01 |
IL245302A0 (en) | 2016-06-30 |
US20180127466A1 (en) | 2018-05-10 |
US10590167B2 (en) | 2020-03-17 |
CL2016001001A1 (es) | 2016-12-16 |
US20160244485A1 (en) | 2016-08-25 |
EP3062810A4 (en) | 2017-05-03 |
EP3564256A1 (en) | 2019-11-06 |
WO2015065891A1 (en) | 2015-05-07 |
CN112321678A (zh) | 2021-02-05 |
RU2016119830A (ru) | 2017-12-04 |
AU2020201109A1 (en) | 2020-03-05 |
RU2016119830A3 (es) | 2018-07-02 |
BR112016009443A8 (pt) | 2020-03-24 |
CN105764522A (zh) | 2016-07-13 |
SG10201810496XA (en) | 2018-12-28 |
US9745342B2 (en) | 2017-08-29 |
SG11201603376UA (en) | 2016-05-30 |
AU2014342624A1 (en) | 2016-06-02 |
MX2016005510A (es) | 2017-01-06 |
JP6603668B2 (ja) | 2019-11-06 |
MX2021000029A (es) | 2021-03-25 |
CA2928701A1 (en) | 2015-05-07 |
KR20160077153A (ko) | 2016-07-01 |
SA516371037B1 (ar) | 2018-05-16 |
EP3062810A1 (en) | 2016-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY34817A (es) | Tienopirimidinas | |
UY34763A (es) | Inhibidores de la agregación plaquetaria | |
UY4236Q (es) | Configuración aplicada en zapato | |
UY34824A (es) | Nucleósidos de espirooxetano de uracilo | |
UY34765A (es) | Compuestos novedosos. | |
CL2012002979A1 (es) | Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona. | |
UY4167Q (es) | Par de auriculares | |
DK2986726T3 (da) | Hidtil ukendte bacillusstammesammensætninger | |
UY4169Q (es) | Altoparlante | |
UY34602A (es) | ?Derivados de bencimidazolil- e imidazopiridinil-metilamina? | |
UY34632A (es) | Compuestos de oxazolidin- 2- ona y usos de los mismos | |
CR20140468A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
UY34654A (es) | Inhibidores de la beta-secretasa | |
UY4281Q (es) | Juguera | |
CY1120759T1 (el) | Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης | |
AU357215S (en) | Positioning element for construction toy | |
TR201905787T4 (tr) | Liyofilize TAT-NR2B9C formülasyonu. | |
AR097668A1 (es) | Colorante-polímero | |
CL2015002358A1 (es) | Compuestos bicíclicos. | |
CL2016000351A1 (es) | Método para la cuantificación de actinio-227 en composiciones de radio-223. | |
AU2014224814A8 (en) | Novel halogen-substituted compounds | |
UY34791A (es) | N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2- dihidroquinolina-3-carboxamida | |
UY34677A (es) | Imidazopiridazinas sustituidas | |
CL2020002247A1 (es) | Compuestos macrociclicos derivados de peptidilo sustituidos (divisional de solicitud n° 01001-2016) | |
UY4314Q (es) | Configuracion aplicada en zapato |